Pharmacological targeting of spreading depression in migraine

Expert Review of Neurotherapeutics

Volumn 12, Issue 3, 2012, Pages 297-306

  Eikermann Haerter, Katharina ^a   Can, Anil ^a   Ayata, Cenk ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

animal models; hormones; ion channels; migraine; prophylaxis; spreading depression

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CITALOPRAM; CLONIDINE; DIHYDROERGOTAMINE; ERGOTAMINE; FLUNARIZINE; FLUOXETINE; GABAPENTIN; ION CHANNEL; LAMOTRIGINE; LIDOCAINE; METHYSERGIDE; METOPROLOL; OXCARBAZEPINE; PIZOTIFEN; PLACEBO; PROPRANOLOL; RIBOFLAVIN; SEROTONIN ANTAGONIST; SUMATRIPTAN; TONABERSAT; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN; BRAIN ELECTROPHYSIOLOGY; CAT; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; DRUG TARGETING; ENVIRONMENTAL FACTOR; EXPERIMENTAL MODEL; HEADACHE; HORMONE ACTION; HUMAN; LASER DOPPLER FLOWMETRY; MAGNESIUM DEFICIENCY; META ANALYSIS (TOPIC); MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NEUROPHARMACOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAT; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; SPREADING CORTICAL DEPRESSION;

ANALGESICS; ANIMALS; CORTICAL SPREADING DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MIGRAINE DISORDERS;

EID: 84857958040     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.13     Document Type: Review

References (94)

1. Lipton RB, Stewart WF. The epidemiology of migraine. Eur. Neurol. 34(Suppl. 2), 6-11 (1994). (Pubitemid 24294532)
2. Ayata C. Cortical spreading depression triggers migraine attack: pro. Headache 50(4), 725-730 (2010).
3. Hadjikhani N, Sanchez Del Rio M, Wu O et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad. Sci. USA 98(8), 4687-4692 (2001). (Pubitemid 32295037)
4. Leo L, Gherardini L, Barone V et al. Increased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2. PLoS Genet. 7(6), e1002129 (2011).
5. Eikermann-Haerter K, Dilekoz E, Kudo C et al. Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J. Clin. Invest. 119(1), 99-109 (2009).
6. Eikermann-Haerter K, Yuzawa I, Dilekoz E, Joutel A, Moskowitz MA, Ayata C. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome mutations increase susceptibility to spreading depression. Ann. Neurol. 69(2), 413-418 (2011).
7. Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. Activation of central trigeminovascular neurons by cortical spreading depression. Ann. Neurol. 69(5), 855-865 (2011).
8. Zhang X, Levy D, Noseda R, Kainz V, Jakubowski M, Burstein R. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J. Neurosci. 30(26), 8807-8814 (2010).
9. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8(2), 136-142 (2002). (Pubitemid 34155124)
10. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59(4), 652-661 (2006).
11. Leao AAP. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 359-390 (1944).
12. Strong AJ. Detecting and characterizing spreading depression in the injured human brain. J. Cereb. Blood Flow Metab. 23(1), 748 (2003).
13. Strong AJ, Fabricius M, Boutelle MG et al. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 33(12), 2738-2743 (2002). (Pubitemid 35462836)
14. Fabricius M, Fuhr S, Bhatia R et al. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain 129(Pt 3), 778-790 (2006). (Pubitemid 43278239)
15. Mayevsky A, Doron A, Manor T, Meilin S, Zarchin N, Ouaknine GE. Cortical spreading depression recorded from the human brain using a multiparametric monitoring system. Brain Res. 740(1-2), 268-274 (1996). (Pubitemid 26411309)
16. Ayata C. Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. Cephalalgia 29(10), 1095-1114 (2009).
17. Kaube H, Goadsby PJ. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur. Neurol. 34(1), 30-35 (1994). (Pubitemid 24014718)
18. Bogdanov VB, Multon S, Chauvel V et al. Migraine preventive drugs differentially affect cortical spreading depression in rat. Neurobiol. Dis. 41(2), 430-435 (2011).
19. Hoffmann U, Dilekoz E, Kudo C, Ayata C. Oxcarbazepine does not suppress cortical spreading depression. Cephalalgia 31(5), 537-542 (2011).
20. Hoffmann U, Dilekoz E, Kudo C, Ayata C. Gabapentin suppresses cortical spreading depression susceptibility. J. Cereb. Blood Flow Metab. 30(9), 1588-1592 (2010).
21. Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport 16(12), 1383-1387 (2005). (Pubitemid 41225215)
22. Read SJ, Smith MI, Hunter AJ, Upton N, Parsons AA. SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 20(2), 92-99 (2000). (Pubitemid 32269515)
23. Smith MI, Read SJ, Chan WN et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB- 220453. Cephalalgia 20(6), 546-553 (2000). (Pubitemid 32269472)
24. Bradley DP, Smith MI, Netsiri C et al. Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: comparison of sumatriptan and tonabersat. Exp. Neurol. 172(2), 342-353 (2001). (Pubitemid 34075083)
25. Read SJ, Hirst WD, Upton N, Parsons AA. Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan. Brain Res. 891(1-2), 69-77 (2001). (Pubitemid 32115496)
26. Marrannes R, Wauquier A, Reid K, De Prins E. Effects of drugs on cortical spreading depression. In: The Prelude to The Migraine Attack. Baillière Tindall, Oxford, UK, 158-173 (1986).
27. Hansen A, Lauritzen M, Tfelt-Hansen P. Spreading cortical depression and antimigraine drugs. In:The Pharmacological Basis of Migraine Therapy. Amery WK, Van Nueten JM, Waquier A (Eds). Putman, London, UK, 161-170 (1984).
28. Reid KH, Marrannes R, Wauquier A. Effects of flunarizine on rat cerebral cortex. Drug Development Research 10, 107-116 (1987). (Pubitemid 17098994)
29. Wauquier A, Ashton D, Marrannes R. The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 5(Suppl. 2), 119-123 (1985). (Pubitemid 15072406)
30. Marrannes R, De Prins E, Fransen J, Clincke G. Neuropharmacology of spreading depression. In:Migraine: Basic Mechanisms and Treatment . Lehmenkuhler A, Grotemeyer KH, Tegtmeier F (Eds). Urban & Schwarzenberg, MD, USA 431-443 (1993).
31. dos Santos AA, Pinheiro PC, de Lima DS et al. Fluoxetine inhibits cortical spreading depression in weaned and adult rats suckled under favorable and unfavorable lactation conditions. Exp. Neurol. 200(2), 275-282 (2006). (Pubitemid 44107910)
32. Guedes RC, Amancio-Dos-Santos A, Manhaes-De-Castro R, Costa-Cruz RR. Citalopram has an antagonistic action on cortical spreading depression in well-nourished and early-malnourished adult rats. Nutr. Neurosci. 5(2), 115-123 (2002). (Pubitemid 34303214)
33. Read SJ, Parsons AA. Sumatriptan modifies cortical free radical release during cortical spreading depression. A novel antimigraine action for sumatriptan? Brain Res. 870(1-2), 44-53 (2000). (Pubitemid 30408402)
34. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J. Neurosci. 13(3), 1167-1177 (1993). (Pubitemid 23067603)
35. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 28(6), 585-597 (2008). (Pubitemid 351614940)
36. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61(4), 490-495 (2004). (Pubitemid 38923736)
37. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache 39(9), 633-643 (1999).
38. Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin - calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain 142(1-2), 13-16 (2009).
39. Eikermann-Haerter K, Yuzawa I, Qin T et al. Enhanced subcortical spreading depression in familial hemiplegic migraine type 1 mutant mice. J. Neurosci. 31(15), 5755-5763 (2011).
40. Silberstein SD, Schoenen J, Gobel H et al. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia 29(Suppl. 2), 17-27 (2009).
41. Dahlof CG, Hauge AW, Olesen J. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. Cephalalgia 29(Suppl. 2), 7-16 (2009).
42. Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 29(7), 742-750 (2009).
43. Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 8(8), 718-723 (2009).
44. D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 19(1), 64-66 (1999). (Pubitemid 29136854)
45. Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J. Neurol. Neurosurg. Psychiatry 76(12), 1730-1732 (2005). (Pubitemid 41697646)
46. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17(2), 109-112 (1997). (Pubitemid 27166265)
47. Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache 47(3), 402-412 (2007). (Pubitemid 46426409)
48. Kelley NE, Tepper DE. Rescue Therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. Headache 52(1), 114-128 (2012).
49. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin. Neurosci. 5(1), 24-27 (1998). (Pubitemid 28106789)
50. Ramadan NM, Halvorson H, Vande-Linde A, Levine SR, Helpern JA, Welch KM. Low brain magnesium in migraine. Headache 29(9), 590-593 (1989). (Pubitemid 20318945)
51. van der Hel WS, van den Bergh WM, Nicolay K, Tulleken KA, Dijkhuizen RM. Suppression of cortical spreading depressions after magnesium treatment in the rat. Neuroreport 9(10), 2179-2182 (1998). (Pubitemid 28338202)
52. Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D'Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 70(7), 548-555 (2008). (Pubitemid 351653380)
53. Taylor FR. Nutraceuticals and headache: the biological basis. Headache 51(3), 484-501 (2011).
54. Bruijn J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts WF. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia 30(12), 1426-1434 (2010).
55. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50(2), 466-470 (1998).
56. Boehnke C, Reuter U, Flach U, Schuh- Hofer S, Einhaupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur. J. Neurol. 11(7), 475-477 (2004). (Pubitemid 39037034)
57. Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55(1), 139-141 (2000). (Pubitemid 30461018)
58. Goldstein M, Chen TC. The epidemiology of disabling headache. Adv. Neurol. 33, 377-390 (1982).
59. Waters WE, O'Connor PJ. Epidemiology of headache and migraine in women. J. Neurol. Neurosurg. Psychiatry 34(2), 148-153 (1971).
60. Eriksen MK, Thomsen LL, Olesen J. Implications of clinical subtypes of migraine with aura. Headache 46(2), 286-297 (2006).
61. Smith SS. Estrogen administration increases neuronal responses to excitatory amino acids as a long-term effect. Brain Res. 503(2), 354-357 (1989). (Pubitemid 19285536)
62. Sato K, Matsuki N, Ohno Y, Nakazawa K. Estrogens inhibit l-glutamate uptake activity of astrocytes via membrane estrogen receptor alpha. J. Neurochem. 86(6), 1498-1505 (2003). (Pubitemid 37174266)
63. Woolley CS, Weiland NG, McEwen BS, Schwartzkroin PA. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J. Neurosci. 17(5), 1848-1859 (1997). (Pubitemid 27089829)
64. Nagel-Leiby S, Welch KM, Grunfeld S, D'Andrea G. Ovarian steroid levels in migraine with and without aura. Cephalalgia 10(3), 147-152 (1990).
65. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 3(6), 354-361 (2004). (Pubitemid 38648856)
66. Ertresvag JM, Zwart JA, Helde G, Johnsen HJ, Bovim G. Headache and transient focal neurological symptoms during pregnancy, a prospective cohort. Acta Neurol. Scand. 111(4), 233-237 (2005). (Pubitemid 40380458)
67. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 33(7), 385-389 (1993). (Pubitemid 23221829)
68. Smith MJ, Adams LF, Schmidt PJ, Rubinow DR, Wassermann EM. Effects of ovarian hormones on human cortical excitability. Ann. Neurol. 51(5), 599-603 (2002).
69. Fettes I. Migraine in the menopause. Neurology 53(4 Suppl. 1), S29-S33 (1999). (Pubitemid 29448339)
70. Thomsen LL, Eriksen MK, Roemer SF, Andersen I, Olesen J, Russell MB. A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria. Brain 125(Pt 6), 1379-1391 (2002). (Pubitemid 34587146)
71. Lichten EML, Whitty J, Peiper AD. The use of leuprolide acetate in the diagnosis and treatment of menstrual migraine: the role of artificially induced menopause. Headache 6, 313-317 (1995).
72. Murray SC, Muse KN. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and 'add-back' therapy. Fertil. Steril. 67(2), 390-393 (1997). (Pubitemid 27052202)
73. Sood SV. Hemiplegic migraine associated with menstruation. J. Obstet. Gynaecol. Br. Commonw. 78(8), 762-763 (1971).
74. Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis - part 2. Headache 46(3), 365-386 (2006).
75. Twyman RE, Macdonald RL. Neurosteroid regulation of GABAA receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J. Physiol. 456, 215-245 (1992).
76. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. Neurology 55(10), 1517-1523 (2000).
77. Eikermann-Haerter K, Baum MJ, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, Ayata C. Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice. Ann. Neurol. 66(4), 564-568 (2009).
78. Moehlig RC. Methyl testosterone for migraine of women; report of sixty cases. J. Mich. State Med. Soc. 54(5), 577-579 (1955).
79. Calton GJ, Burnett JW. Danazol and migraine. N. Engl. J. Med. 310(11), 721-722 (1984). (Pubitemid 14164654)
80. Jonsson B, Von Reis G, Sahlgren E. [Testosterone therapy of headache]. Acta Psychiatr. Neurol. Scand. 74, 102-105 (1951).
81. Lichten EM, Bennett RS, Whitty AJ, Daoud Y. Efficacy of danazol in the control of hormonal migraine. J. Reprod. Med. 36(6), 419-424 (1991).
82. Vincent FM. Migraine responsive to danazol. Neurology 35(4), 618 (1985). (Pubitemid 15085101)
83. Arango O, Bielsa O, Pascual-Calvet J, Herrero M, Gelabert-Mas A. [Disappearance of migraine crises in two patients with male infertility treated with human chorionic gonadotropin/human menopausal gonadotrophin]. Rev. Neurol. 24(132), 977-979 (1996).
84. Pringsheim T, Gooren L. Migraine prevalence in male to female transsexuals on hormone therapy. Neurology 63(3), 593-594 (2004). (Pubitemid 39031411)
85. Nudler SI, Pagani MR, Urbano FJ, McEnery MW, Uchitel OD. Testosterone modulates Ca(v2.2) calcium channels' functional expression at rat levator ani neuromuscular junction. Neuroscience 134(3), 817-826 (2005). (Pubitemid 41133385)
86. Kitahara Y, Taga K, Abe H, Shimoji K. The effects of anesthetics on cortical spreading depression elicitation and c-fos expression in rats. J. Neurosurg. Anesthesiol. 13(1), 26-32 (2001). (Pubitemid 32104098)
87. Kudo C, Nozari A, Moskowitz MA, Ayata C. The impact of anesthetics and hyperoxia on cortical spreading depression. Exp. Neurol. 212(1), 201-206 (2008).
88. Triner WR, Bartfield JM, Birdwell M, Raccio-Robak N. Nitrous oxide for the treatment of acute migraine headache. Am. J. Emerg. Med. 17(3), 252-254 (1999). (Pubitemid 29218262)
89. Loder E. Design considerations in migraine with aura trials: learning from experience. Cephalalgia 30(9), 1027-1028 (2011).
90. Welch KM, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol. Clin. 8(4), 817-828 (1990). (Pubitemid 20360045)
91. Coppola G, Schoenen J. Cortical Excitability in Chronic Migraine. Curr. Pain Headache Rep. 16(1), 93-100 (2012).
92. Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J. Cereb. Blood Flow Metab. 31(1), 17-35 (2010).
93. Strong AJ, Hartings JA, Dreier JP. Cortical spreading depression: an adverse but treatable factor in intensive care? Curr. Opin. Crit. Care. 13(2), 126-133 (2007). (Pubitemid 46328325)
94. Eikermann-Haerter K, Hyun Lee J, Yuzawa I et al. Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations. Circulation 125(2), 335-345 (2012).